PHARMING GROUP Share Price Euronext Amsterdam
Equities
NL0000377018
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- EUR | - |
08/05 | Transcript : Pharming Group N.V., Q1 2024 Earnings Call, May 08, 2024 | |
08/05 | Pharming Group N.V. Provides Revenue Guidance for 2024 | CI |
Sales 2024 * | 266M 290M 24.12B | Sales 2025 * | 304M 330M 27.49B | Capitalization | 569M 618M 51.51B |
---|---|---|---|---|---|
Net income 2024 * | -10M -10.87M -905M | Net income 2025 * | 4M 4.35M 362M | EV / Sales 2024 * | 1.81 x |
Net cash position 2024 * | 87.65M 95.25M 7.93B | Net cash position 2025 * | 109M 118M 9.85B | EV / Sales 2025 * | 1.52 x |
P/E ratio 2024 * |
-52.8
x | P/E ratio 2025 * |
-211
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.67% |
Latest transcript on PHARMING GROUP
Managers | Title | Age | Since |
---|---|---|---|
Sijmen de Vries
CEO | Chief Executive Officer | 65 | 13/08/13 |
Jeroen Wakkerman
DFI | Director of Finance/CFO | 55 | 16/20/16 |
Anurag Relan
CTO | Chief Tech/Sci/R&D Officer | 52 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Pykett
BRD | Director/Board Member | 60 | 11/20/11 |
Leonard Kruimer
BRD | Director/Board Member | 66 | 19/21/19 |
Sijmen de Vries
CEO | Chief Executive Officer | 65 | 13/08/13 |
1st Jan change | Capi. | |
---|---|---|
+32.09% | 694B | |
+29.39% | 593B | |
-1.34% | 371B | |
+20.34% | 331B | |
+7.39% | 290B | |
+14.25% | 239B | |
-3.03% | 209B | |
+10.02% | 209B | |
+8.49% | 169B |